Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Victoria de Torres, Olombrada"'
Autor:
Beatriz Losada Vila, Juan Antonio Guerra Martínez, David Gutiérrez Abad, Maria Victoria De Torres Olombrada
Publikováno v:
Journal of Tumor Research.
Thromboembolic disease (VTE) is a very important cause of morbidity and mortality in cancer patients, with a recurrence rate of 10-17% in patients treated with anti-vitamin K and 6-9% in low molecular weight heparin (LMWH). This case reflects the rec
Autor:
Maria Victoria De Torres Olombrada, Beatriz Losada Vila, Juan Antonio Guerra Martínez, David Gutiérrez Abad
Publikováno v:
Journal of Tumor Research.
Pain is a frequent symptom in the evolution of the cancer patient, often acquiring chronic character as a consequence of the progression of the disease. More than 70% of patients are not under control. In this case review we will expose the managemen
Autor:
Laura Rodriguez Lajusticia, Juan Antonio Guerra Martínez, María C. Pantín González, Beatriz Losada Vila, Ignacio Juez Martel, David Gutiérrez Abad, Maria Victoria De Torres Olombrada, Diego Malón Giménez
Publikováno v:
Annals of Clinical and Laboratory Research.
Pain is a frequent symptom in the evolution of a cancer patient, affecting 70% of them in terms of decreasing quality of life. Treatment should adapt to type and intensity of pain in order to optimize analgesic control. In this case report we will re
Autor:
Maria Victoria De Torres, Olombrada, Ana Alvarez, González, Carmen Ibáñez, Villoslada, Begoña Caballero, Perea, Blanca Ludeña, Martinez, Pastora Caballero, Guerra
Publikováno v:
Archivos espanoles de urologia. 65(1)
Adjuvant radiotherapy (RT) has proven to be more effective in patients at high risk of relapse than salvage RT when this relapse occurs. To optimize its use we must identify the subset of patients at greater risk of residual microscopic disease after
Publikováno v:
Archivos espanoles de urologia. 65(1)
Prostate specific antigen (PSA) is the main tool in the follow-up of prostate cancer patients after definitive therapy. It's widely used as an early marker to value treatment success. Biochemical recurrence predicts metastatic disease progression and